Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.4013
-0.0242 (-5.69%)
At close: Nov 6, 2026, 4:00 PM EST
0.4065
+0.0052 (1.30%)
After-hours: Nov 6, 2026, 6:05 PM EST
Akebia Therapeutics Employees
Akebia Therapeutics had 194 employees as of December 31, 2025. The number of employees increased by 13 or 7.18% compared to the previous year. That makes Akebia Therapeutics the 27,036th largest employer in the world and 3,409th in the United States.
Employees
194
Change (1Y)
13
Growth (1Y)
7.18%
Revenue / Employee
$1,016,479
Profits / Employee
-$229,691
Market Cap
111.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 194 | 13 | 7.18% | 194 | 0 |
| Dec 31, 2024 | 181 | 14 | 8.38% | 181 | 0 |
| Dec 31, 2023 | 167 | -38 | -18.54% | 167 | 0 |
| Dec 31, 2022 | 205 | -221 | -51.88% | 204 | 1 |
| Dec 31, 2021 | 426 | 46 | 12.11% | 426 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Organigram Global | 1,120 |
| Organogenesis Holdings | 854 |
| Glass House Brands | 426 |
| Zhengye Biotechnology Holding | 269 |
| Anika Therapeutics | 235 |
| ADC Therapeutics | 193 |
| Cumberland Pharmaceuticals | 88 |
| Journey Medical | 58 |
AKBA News
- 2 days ago - Akebia price target lowered to $4 from $6 at H.C. Wainwright - TheFly
- 3 days ago - Akebia price target lowered to $3 from $4 at BTIG - TheFly
- 3 days ago - Akebia reports topline results from VOCAL trial - TheFly
- 3 days ago - Akebia Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Akebia Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - Akebia Therapeutics Quarterly report: Q3 2026 - Filings
- 3 days ago - Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 3 days ago - Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin - GlobeNewsWire